Safety of combined PD‐1 pathway inhibition and radiation therapy for non‐small‐cell lung cancer: A multicentric retrospective study from the GFPC

Abstract Introduction Randomized prospective studies on patients with metastatic non‐small‐cell lung cancers (NSCLCs) showed that anti‐programmed death‐1 (PD‐1) agents notably improved 2‐year overall survival (OS) rates, compared to docetaxel. NSCLC patients now receive nivolumab and irradiation, co...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Paul Lesueur, Alexandre Escande, Juliette Thariat, Enora Vauléon, Isabelle Monnet, Alexis Cortot, Delphine Lerouge, Serge Danhier, Pascal Dô, Catherine Dubos‐Arvis, Christos Chouaïd, Radj Gervais
Format:	Artigo
Jezik:	Inglês
Izdano:	Wiley 2018-11-01
Serija:	Cancer Medicine
Teme:	anti‐PD‐1 checkpoint inhibitor: radiotherapy combination nivolumab safety
Online dostop:	https://doi.org/10.1002/cam4.1825
Oznake:	Označite Brez oznak, prvi označite!